![PDF) Management and clinical outcomes of follicular lymphoma across continuous lines of treatments: a retrospective analysis in China PDF) Management and clinical outcomes of follicular lymphoma across continuous lines of treatments: a retrospective analysis in China](https://i1.rgstatic.net/publication/374967946_Management_and_clinical_outcomes_of_follicular_lymphoma_across_continuous_lines_of_treatments_a_retrospective_analysis_in_China/links/6539904d73a2865c7ad33350/largepreview.png)
PDF) Management and clinical outcomes of follicular lymphoma across continuous lines of treatments: a retrospective analysis in China
![Dissecting intratumor heterogeneity of nodal B cell lymphomas on the transcriptional, genetic, and drug response level | bioRxiv Dissecting intratumor heterogeneity of nodal B cell lymphomas on the transcriptional, genetic, and drug response level | bioRxiv](https://www.biorxiv.org/content/biorxiv/early/2019/12/11/850438/F2.large.jpg)
Dissecting intratumor heterogeneity of nodal B cell lymphomas on the transcriptional, genetic, and drug response level | bioRxiv
Life expectancy of follicular lymphoma patients in complete response at 30 months is similar to that of the Spanish general popu
![NCCN Guidelines Insights: B-Cell Lymphomas, Version 3.2019 in: Journal of the National Comprehensive Cancer Network Volume 17 Issue 6 (2019) NCCN Guidelines Insights: B-Cell Lymphomas, Version 3.2019 in: Journal of the National Comprehensive Cancer Network Volume 17 Issue 6 (2019)](https://jnccn.org/view/journals/jnccn/17/6/full-jnccnINSBCELL1706tbl1.jpg)
NCCN Guidelines Insights: B-Cell Lymphomas, Version 3.2019 in: Journal of the National Comprehensive Cancer Network Volume 17 Issue 6 (2019)
Medical Oncology - Kantarjian, Wolff - The MD Anderson Manual of 2016 | PDF | Doctor Of Medicine | Oncology
![Cancers | Free Full-Text | Large-Scale Proteomic Analysis of Follicular Lymphoma Reveals Extensive Remodeling of Cell Adhesion Pathway and Identifies Hub Proteins Related to the Lymphomagenesis Cancers | Free Full-Text | Large-Scale Proteomic Analysis of Follicular Lymphoma Reveals Extensive Remodeling of Cell Adhesion Pathway and Identifies Hub Proteins Related to the Lymphomagenesis](https://pub.mdpi-res.com/cancers/cancers-13-00630/article_deploy/html/images/cancers-13-00630-ag-550.jpg?1612774949)
Cancers | Free Full-Text | Large-Scale Proteomic Analysis of Follicular Lymphoma Reveals Extensive Remodeling of Cell Adhesion Pathway and Identifies Hub Proteins Related to the Lymphomagenesis
![Dissecting intratumour heterogeneity of nodal B-cell lymphomas at the transcriptional, genetic and drug-response levels | Nature Cell Biology Dissecting intratumour heterogeneity of nodal B-cell lymphomas at the transcriptional, genetic and drug-response levels | Nature Cell Biology](https://media.springernature.com/m685/springer-static/image/art%3A10.1038%2Fs41556-020-0532-x/MediaObjects/41556_2020_532_Fig4_HTML.png)
Dissecting intratumour heterogeneity of nodal B-cell lymphomas at the transcriptional, genetic and drug-response levels | Nature Cell Biology
![Cancers | Free Full-Text | Large-Scale Proteomic Analysis of Follicular Lymphoma Reveals Extensive Remodeling of Cell Adhesion Pathway and Identifies Hub Proteins Related to the Lymphomagenesis Cancers | Free Full-Text | Large-Scale Proteomic Analysis of Follicular Lymphoma Reveals Extensive Remodeling of Cell Adhesion Pathway and Identifies Hub Proteins Related to the Lymphomagenesis](https://pub.mdpi-res.com/cancers/cancers-13-00630/article_deploy/html/images/cancers-13-00630-g002.png?1612774949)
Cancers | Free Full-Text | Large-Scale Proteomic Analysis of Follicular Lymphoma Reveals Extensive Remodeling of Cell Adhesion Pathway and Identifies Hub Proteins Related to the Lymphomagenesis
![Dissecting intratumor heterogeneity of nodal B cell lymphomas on the transcriptional, genetic, and drug response level | bioRxiv Dissecting intratumor heterogeneity of nodal B cell lymphomas on the transcriptional, genetic, and drug response level | bioRxiv](https://www.biorxiv.org/content/biorxiv/early/2019/12/11/850438/F5.large.jpg)
Dissecting intratumor heterogeneity of nodal B cell lymphomas on the transcriptional, genetic, and drug response level | bioRxiv
![PDF) Risk of, and survival following, histological transformation in follicular lymphoma in the rituximab era. A retrospective multicentre study by the Spanish GELTAMO group PDF) Risk of, and survival following, histological transformation in follicular lymphoma in the rituximab era. A retrospective multicentre study by the Spanish GELTAMO group](https://i1.rgstatic.net/publication/318988170_Risk_of_and_survival_following_histological_transformation_in_follicular_lymphoma_in_the_rituximab_era_A_retrospective_multicentre_study_by_the_Spanish_GELTAMO_group/links/5d3762ab4585153e591c4484/largepreview.png)
PDF) Risk of, and survival following, histological transformation in follicular lymphoma in the rituximab era. A retrospective multicentre study by the Spanish GELTAMO group
![Cancers | Free Full-Text | Large-Scale Proteomic Analysis of Follicular Lymphoma Reveals Extensive Remodeling of Cell Adhesion Pathway and Identifies Hub Proteins Related to the Lymphomagenesis Cancers | Free Full-Text | Large-Scale Proteomic Analysis of Follicular Lymphoma Reveals Extensive Remodeling of Cell Adhesion Pathway and Identifies Hub Proteins Related to the Lymphomagenesis](https://www.mdpi.com/cancers/cancers-13-00630/article_deploy/html/images/cancers-13-00630-g003-550.jpg)
Cancers | Free Full-Text | Large-Scale Proteomic Analysis of Follicular Lymphoma Reveals Extensive Remodeling of Cell Adhesion Pathway and Identifies Hub Proteins Related to the Lymphomagenesis
![NCCN Guidelines Insights: B-Cell Lymphomas, Version 3.2019 in: Journal of the National Comprehensive Cancer Network Volume 17 Issue 6 (2019) NCCN Guidelines Insights: B-Cell Lymphomas, Version 3.2019 in: Journal of the National Comprehensive Cancer Network Volume 17 Issue 6 (2019)](https://jnccn.org/view/journals/jnccn/17/6/full-jnccnINSBCELL1706fx7.jpg)
NCCN Guidelines Insights: B-Cell Lymphomas, Version 3.2019 in: Journal of the National Comprehensive Cancer Network Volume 17 Issue 6 (2019)
Modeling PRC2 Alterations in Cancer, a Window Toward a Better Comprehension of EZH2 Mutation in Follicular Lymphoma
Articles from the 16th International Conference on Malignant Lymphoma, Lugano, Switzerland Virtual edition, June 18–22, 2021
![EZH2 mutations at diagnosis in follicular lymphoma: a promising biomarker to guide frontline treatment. - Abstract - Europe PMC EZH2 mutations at diagnosis in follicular lymphoma: a promising biomarker to guide frontline treatment. - Abstract - Europe PMC](https://europepmc.org/articles/PMC9476261/bin/12885_2022_10070_Fig1_HTML.jpg)
EZH2 mutations at diagnosis in follicular lymphoma: a promising biomarker to guide frontline treatment. - Abstract - Europe PMC
![NCCN Guidelines Insights: B-Cell Lymphomas, Version 3.2019 in: Journal of the National Comprehensive Cancer Network Volume 17 Issue 6 (2019) NCCN Guidelines Insights: B-Cell Lymphomas, Version 3.2019 in: Journal of the National Comprehensive Cancer Network Volume 17 Issue 6 (2019)](https://jnccn.org/view/journals/jnccn/17/6/full-jnccnINSBCELL1706fx5.jpg)
NCCN Guidelines Insights: B-Cell Lymphomas, Version 3.2019 in: Journal of the National Comprehensive Cancer Network Volume 17 Issue 6 (2019)
![PDF) Follicular lymphoma patients with KIR2DL2 and KIR3DL1 and their ligands (HLA-C1 and HLA-Bw4) show improved outcome when receiving rituximab PDF) Follicular lymphoma patients with KIR2DL2 and KIR3DL1 and their ligands (HLA-C1 and HLA-Bw4) show improved outcome when receiving rituximab](https://i1.rgstatic.net/publication/331758248_Follicular_lymphoma_patients_with_KIR2DL2_and_KIR3DL1_and_their_ligands_HLA-C1_and_HLA-Bw4_show_improved_outcome_when_receiving_rituximab/links/5c8b02b345851564fade4f05/largepreview.png)
PDF) Follicular lymphoma patients with KIR2DL2 and KIR3DL1 and their ligands (HLA-C1 and HLA-Bw4) show improved outcome when receiving rituximab
![Dissecting intratumor heterogeneity of nodal B cell lymphomas on the transcriptional, genetic, and drug response level | bioRxiv Dissecting intratumor heterogeneity of nodal B cell lymphomas on the transcriptional, genetic, and drug response level | bioRxiv](https://www.biorxiv.org/content/biorxiv/early/2019/12/11/850438/F3.large.jpg)
Dissecting intratumor heterogeneity of nodal B cell lymphomas on the transcriptional, genetic, and drug response level | bioRxiv
Patient derived lymphoma spheroids (PDLS) as preclinical follicular lymphoma models for personalized medicine: identification of
Patient derived lymphoma spheroids (PDLS) as preclinical follicular lymphoma models for personalized medicine: identification of
Life expectancy of follicular lymphoma patients in complete response at 30 months is similar to that of the Spanish general popu
![EZH2 mutations at diagnosis in follicular lymphoma: a promising biomarker to guide frontline treatment | BMC Cancer | Full Text EZH2 mutations at diagnosis in follicular lymphoma: a promising biomarker to guide frontline treatment | BMC Cancer | Full Text](https://media.springernature.com/m685/springer-static/image/art%3A10.1186%2Fs12885-022-10070-z/MediaObjects/12885_2022_10070_Fig1_HTML.png)
EZH2 mutations at diagnosis in follicular lymphoma: a promising biomarker to guide frontline treatment | BMC Cancer | Full Text
![PDF) Phase I dose escalation study of BI 836826 (CD37 antibody) in patients with relapsed or refractory B-cell non-Hodgkin lymphoma PDF) Phase I dose escalation study of BI 836826 (CD37 antibody) in patients with relapsed or refractory B-cell non-Hodgkin lymphoma](https://i1.rgstatic.net/publication/339934952_Phase_I_dose_escalation_study_of_BI_836826_CD37_antibody_in_patients_with_relapsed_or_refractory_B-cell_non-Hodgkin_lymphoma/links/5ef23699a6fdcc158d2241e3/largepreview.png)
PDF) Phase I dose escalation study of BI 836826 (CD37 antibody) in patients with relapsed or refractory B-cell non-Hodgkin lymphoma
![Non-Hodgkin's Lymphomas in: Journal of the National Comprehensive Cancer Network Volume 9 Issue 5 (2011) Non-Hodgkin's Lymphomas in: Journal of the National Comprehensive Cancer Network Volume 9 Issue 5 (2011)](https://jnccn.org/view/journals/jnccn/9/5/0484tbl01.jpeg)
Non-Hodgkin's Lymphomas in: Journal of the National Comprehensive Cancer Network Volume 9 Issue 5 (2011)
![Dissecting intratumor heterogeneity of nodal B cell lymphomas on the transcriptional, genetic, and drug response level | bioRxiv Dissecting intratumor heterogeneity of nodal B cell lymphomas on the transcriptional, genetic, and drug response level | bioRxiv](https://www.biorxiv.org/content/biorxiv/early/2019/12/11/850438/F6.large.jpg)
Dissecting intratumor heterogeneity of nodal B cell lymphomas on the transcriptional, genetic, and drug response level | bioRxiv
![NCCN Guidelines Insights: B-Cell Lymphomas, Version 3.2019 in: Journal of the National Comprehensive Cancer Network Volume 17 Issue 6 (2019) NCCN Guidelines Insights: B-Cell Lymphomas, Version 3.2019 in: Journal of the National Comprehensive Cancer Network Volume 17 Issue 6 (2019)](https://jnccn.org/cover/journals/jnccn/17/6/cover.jpg)
NCCN Guidelines Insights: B-Cell Lymphomas, Version 3.2019 in: Journal of the National Comprehensive Cancer Network Volume 17 Issue 6 (2019)
![Progression‐free survival at 2 years post‐autologous transplant: a surrogate end point for overall survival in follicular lymphoma - Jiménez‐Ubieto - 2017 - Cancer Medicine - Wiley Online Library Progression‐free survival at 2 years post‐autologous transplant: a surrogate end point for overall survival in follicular lymphoma - Jiménez‐Ubieto - 2017 - Cancer Medicine - Wiley Online Library](https://onlinelibrary.wiley.com/cms/asset/1f9b2894-af90-46d4-8622-8ddea9ef90f9/cam41217-fig-0001-m.jpg)
Progression‐free survival at 2 years post‐autologous transplant: a surrogate end point for overall survival in follicular lymphoma - Jiménez‐Ubieto - 2017 - Cancer Medicine - Wiley Online Library
![Dissecting intratumor heterogeneity of nodal B cell lymphomas on the transcriptional, genetic, and drug response level | bioRxiv Dissecting intratumor heterogeneity of nodal B cell lymphomas on the transcriptional, genetic, and drug response level | bioRxiv](https://www.biorxiv.org/content/biorxiv/early/2019/12/11/850438/F1.large.jpg)
Dissecting intratumor heterogeneity of nodal B cell lymphomas on the transcriptional, genetic, and drug response level | bioRxiv
![Early Relapse of Follicular Lymphoma After Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Defines Patients at High Risk for Death: An Analysis From the National LymphoCare Study | Journal of Clinical Oncology Early Relapse of Follicular Lymphoma After Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Defines Patients at High Risk for Death: An Analysis From the National LymphoCare Study | Journal of Clinical Oncology](https://ascopubs.org/na101/home/literatum/publisher/asco/journals/content/jco/2015/jco.2015.61.33.issue-23/jco.2015.61.33.issue-23/20160927-01/jco.2015.61.33.issue-23.largecover.png)
Early Relapse of Follicular Lymphoma After Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Defines Patients at High Risk for Death: An Analysis From the National LymphoCare Study | Journal of Clinical Oncology
Articles from the 16th International Conference on Malignant Lymphoma, Lugano, Switzerland Virtual edition, June 18–22, 2021
![NCCN Guidelines Insights: B-Cell Lymphomas, Version 3.2019 in: Journal of the National Comprehensive Cancer Network Volume 17 Issue 6 (2019) NCCN Guidelines Insights: B-Cell Lymphomas, Version 3.2019 in: Journal of the National Comprehensive Cancer Network Volume 17 Issue 6 (2019)](https://jnccn.org/view/journals/jnccn/17/6/full-jnccnINSBCELL1706fx3.jpg)